Pharmacokinetics of Lidaprim in cases of impaired renal function.
Elimination half-life times, plasma concentrations, and minimal cumulation factors are being determined resp. calculated for trimethoprime and sulfametrole (free as well as total amounts)--both combination partners of Lidaprim--in healthy volunteers and in patients with impaired renal function. There is a strong influence of renal function on the cumulation of the metabolized part of the sulfonamide, a weaker one on trimethoprime, and almost none on the free sulfonamide. On account of the sulfonamide metabolite cumulation, a reduction by half of the standard dose of Lidaprim is recommended if the creatinine clearance is below 20-30 ml/min.
D000328:Adult; D000368:Aged; D003404:Creatinine / Q000378:metabolism; D004338:Drug Combinations; D005260:Female; D006207:Half-Life; D006801:Humans; D007674:Kidney Diseases / Q000097:blood*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D013424:Sulfanilamides / Q000494:pharmacology*; D013997:Time Factors; D014295:Trimethoprim / Q000097:blood*
D004338:Drug Combinations; D013424:Sulfanilamides; C011900:lidaprim; D014295:Trimethoprim; D003404:Creatinine